PubMed:10561458
Annnotations
Glycan-Motif
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 83-90 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | Heparin |
| T2 | 83-90 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | Heparin |
| T3 | 708-715 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T4 | 708-715 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
| T5 | 1124-1131 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T6 | 1124-1131 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
GlyCosmos6-Glycan-Motif-Image
| Id | Subject | Object | Predicate | Lexical cue | image |
|---|---|---|---|---|---|
| T1 | 83-90 | Glycan_Motif | denotes | Heparin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO |
| T3 | 708-715 | Glycan_Motif | denotes | heparin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO |
| T5 | 1124-1131 | Glycan_Motif | denotes | heparin | https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G54161DR|https://api.glycosmos.org/wurcs2image/0.10.0/png/binary/G00021MO |
sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| TextSentencer_T1 | 0-82 | Sentence | denotes | A novel strategy to generate biologically active neo-glycosaminoglycan conjugates. |
| TextSentencer_T2 | 83-199 | Sentence | denotes | Heparin and heparan sulfate are structurally related polysaccharides with a variety of biological effects/functions. |
| TextSentencer_T3 | 200-337 | Sentence | denotes | Most of these effects are due to interactions, of varying specificity, between the negatively charged polysaccharide chains and proteins. |
| TextSentencer_T4 | 338-562 | Sentence | denotes | While such interactions generally involve a single saccharide domain of decasaccharide size or less, ternary complexes of two protein molecules binding to separate domains on a single polysaccharide chain are known to occur. |
| TextSentencer_T5 | 563-763 | Sentence | denotes | To facilitate studies on domain organization and its importance for biological function a strategy was developed to chemically conjugate defined heparin oligomers in linear and chemoselective fashion. |
| TextSentencer_T6 | 764-1030 | Sentence | denotes | The procedure requires that the oligosaccharide to provide the reducing-terminal domain of the conjugate is generated by lyase degradation of a parent polysaccharide, whereas the nonreducing-terminal domain is obtained through deaminative cleavage with nitrous acid. |
| TextSentencer_T7 | 1031-1273 | Sentence | denotes | The applicability of the method was demonstrated by constructing a conjugate composed of two heparin 12-mers, of which the reducing-terminal component contained the antithrombin-binding region, whereas the nonreducing-terminal domain did not. |
| TextSentencer_T8 | 1274-1411 | Sentence | denotes | Contrary to any of the unconjugated oligomers, the product was found to efficiently promote the inactivation of thrombin by antithrombin. |
| T1 | 0-82 | Sentence | denotes | A novel strategy to generate biologically active neo-glycosaminoglycan conjugates. |
| T2 | 83-199 | Sentence | denotes | Heparin and heparan sulfate are structurally related polysaccharides with a variety of biological effects/functions. |
| T3 | 200-337 | Sentence | denotes | Most of these effects are due to interactions, of varying specificity, between the negatively charged polysaccharide chains and proteins. |
| T4 | 338-562 | Sentence | denotes | While such interactions generally involve a single saccharide domain of decasaccharide size or less, ternary complexes of two protein molecules binding to separate domains on a single polysaccharide chain are known to occur. |
| T5 | 563-763 | Sentence | denotes | To facilitate studies on domain organization and its importance for biological function a strategy was developed to chemically conjugate defined heparin oligomers in linear and chemoselective fashion. |
| T6 | 764-1030 | Sentence | denotes | The procedure requires that the oligosaccharide to provide the reducing-terminal domain of the conjugate is generated by lyase degradation of a parent polysaccharide, whereas the nonreducing-terminal domain is obtained through deaminative cleavage with nitrous acid. |
| T7 | 1031-1273 | Sentence | denotes | The applicability of the method was demonstrated by constructing a conjugate composed of two heparin 12-mers, of which the reducing-terminal component contained the antithrombin-binding region, whereas the nonreducing-terminal domain did not. |
| T8 | 1274-1411 | Sentence | denotes | Contrary to any of the unconjugated oligomers, the product was found to efficiently promote the inactivation of thrombin by antithrombin. |
| T1 | 0-82 | Sentence | denotes | A novel strategy to generate biologically active neo-glycosaminoglycan conjugates. |
| T2 | 83-199 | Sentence | denotes | Heparin and heparan sulfate are structurally related polysaccharides with a variety of biological effects/functions. |
| T3 | 200-337 | Sentence | denotes | Most of these effects are due to interactions, of varying specificity, between the negatively charged polysaccharide chains and proteins. |
| T4 | 338-562 | Sentence | denotes | While such interactions generally involve a single saccharide domain of decasaccharide size or less, ternary complexes of two protein molecules binding to separate domains on a single polysaccharide chain are known to occur. |
| T5 | 563-763 | Sentence | denotes | To facilitate studies on domain organization and its importance for biological function a strategy was developed to chemically conjugate defined heparin oligomers in linear and chemoselective fashion. |
| T6 | 764-1030 | Sentence | denotes | The procedure requires that the oligosaccharide to provide the reducing-terminal domain of the conjugate is generated by lyase degradation of a parent polysaccharide, whereas the nonreducing-terminal domain is obtained through deaminative cleavage with nitrous acid. |
| T7 | 1031-1273 | Sentence | denotes | The applicability of the method was demonstrated by constructing a conjugate composed of two heparin 12-mers, of which the reducing-terminal component contained the antithrombin-binding region, whereas the nonreducing-terminal domain did not. |
| T8 | 1274-1411 | Sentence | denotes | Contrary to any of the unconjugated oligomers, the product was found to efficiently promote the inactivation of thrombin by antithrombin. |
GlyCosmos6-Glycan-Motif-Structure
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 83-90 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | Heparin |
| T2 | 83-90 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | Heparin |
| T3 | 708-715 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T4 | 708-715 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
| T5 | 1124-1131 | https://glytoucan.org/Structures/Glycans/G00021MO | denotes | heparin |
| T6 | 1124-1131 | https://glytoucan.org/Structures/Glycans/G54161DR | denotes | heparin |
Glycosmos6-GlycoEpitope
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 95-110 | http://www.glycoepitope.jp/epitopes/EP0086 | denotes | heparan sulfate |
GlycoBiology-FMA
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| _T1 | 53-70 | FMAID:63011 | denotes | glycosaminoglycan |
| _T2 | 53-70 | FMAID:167395 | denotes | glycosaminoglycan |
| _T3 | 83-90 | FMAID:167420 | denotes | Heparin |
| _T4 | 83-90 | FMAID:82839 | denotes | Heparin |
| _T5 | 95-102 | FMAID:165191 | denotes | heparan |
| _T6 | 95-102 | FMAID:67110 | denotes | heparan |
| _T7 | 95-110 | FMAID:63023 | denotes | heparan sulfate |
| _T8 | 95-110 | FMAID:167405 | denotes | heparan sulfate |
| _T9 | 115-135 | FMAID:167966 | denotes | structurally related |
| _T10 | 115-135 | FMAID:50627 | denotes | structurally related |
| _T11 | 136-151 | FMAID:196735 | denotes | polysaccharides |
| _T12 | 136-151 | FMAID:82746 | denotes | polysaccharides |
| _T13 | 136-151 | FMAID:196779 | denotes | polysaccharides |
| _T14 | 136-151 | FMAID:82785 | denotes | polysaccharides |
| _T15 | 302-316 | FMAID:82746 | denotes | polysaccharide |
| _T16 | 302-316 | FMAID:196735 | denotes | polysaccharide |
| _T17 | 302-316 | FMAID:196779 | denotes | polysaccharide |
| _T18 | 302-316 | FMAID:82785 | denotes | polysaccharide |
| _T19 | 328-336 | FMAID:165447 | denotes | proteins |
| _T20 | 328-336 | FMAID:67257 | denotes | proteins |
| _T21 | 389-399 | FMAID:196733 | denotes | saccharide |
| _T22 | 389-399 | FMAID:82744 | denotes | saccharide |
| _T23 | 464-471 | FMAID:67257 | denotes | protein |
| _T24 | 464-471 | FMAID:165447 | denotes | protein |
| _T25 | 522-536 | FMAID:82746 | denotes | polysaccharide |
| _T26 | 522-536 | FMAID:82785 | denotes | polysaccharide |
| _T27 | 522-536 | FMAID:196735 | denotes | polysaccharide |
| _T28 | 522-536 | FMAID:196779 | denotes | polysaccharide |
| _T29 | 595-607 | FMAID:67498 | denotes | organization |
| _T30 | 595-607 | FMAID:166081 | denotes | organization |
| _T31 | 708-715 | FMAID:167420 | denotes | heparin |
| _T32 | 708-715 | FMAID:82839 | denotes | heparin |
| _T33 | 796-811 | FMAID:196731 | denotes | oligosaccharide |
| _T34 | 796-811 | FMAID:82742 | denotes | oligosaccharide |
| _T35 | 915-929 | FMAID:82746 | denotes | polysaccharide |
| _T36 | 915-929 | FMAID:196735 | denotes | polysaccharide |
| _T37 | 915-929 | FMAID:196779 | denotes | polysaccharide |
| _T38 | 915-929 | FMAID:82785 | denotes | polysaccharide |
| _T39 | 1124-1131 | FMAID:167420 | denotes | heparin |
| _T40 | 1124-1131 | FMAID:82839 | denotes | heparin |
GlycoBiology-NCBITAXON
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 128-135 | http://purl.bioontology.org/ontology/NCBITAXON/353209 | denotes | related |
| T2 | 631-650 | http://purl.bioontology.org/ontology/STY/T039 | denotes | biological function |
GO-BP
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 71-81 | http://purl.obolibrary.org/obo/GO_0000746 | denotes | conjugates |
| T2 | 690-699 | http://purl.obolibrary.org/obo/GO_0000746 | denotes | conjugate |
| T3 | 859-868 | http://purl.obolibrary.org/obo/GO_0000746 | denotes | conjugate |
| T4 | 1098-1107 | http://purl.obolibrary.org/obo/GO_0000746 | denotes | conjugate |
| T5 | 103-110 | http://purl.obolibrary.org/obo/GO_0051923 | denotes | sulfate |
| T6 | 666-675 | http://purl.obolibrary.org/obo/GO_0032502 | denotes | developed |
| T7 | 891-902 | http://purl.obolibrary.org/obo/GO_0009056 | denotes | degradation |
| T8 | 1135-1139 | http://purl.obolibrary.org/obo/GO_0016152 | denotes | mers |
GO-MF
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 482-489 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | binding |
| T2 | 1209-1216 | http://purl.obolibrary.org/obo/GO_0070026 | denotes | binding |
| T3 | 482-489 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | binding |
| T4 | 1209-1216 | http://purl.obolibrary.org/obo/GO_0003680 | denotes | binding |
| T5 | 482-489 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | binding |
| T6 | 1209-1216 | http://purl.obolibrary.org/obo/GO_0017091 | denotes | binding |
| T7 | 482-489 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | binding |
| T8 | 1209-1216 | http://purl.obolibrary.org/obo/GO_0005488 | denotes | binding |
GlycoBiology-Motifs
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 708-715 | http://rdf.glycoinfo.org/glycan/G54161DR | denotes | heparin |
| T2 | 1124-1131 | http://rdf.glycoinfo.org/glycan/G54161DR | denotes | heparin |
GlycoBiology-Epitope
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-GlycoEpitope-B_T1 | 95-110 | http://www.glycoepitope.jp/epitopes/EP0086 | denotes | heparan sulfate |
performance-test
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| PD-UBERON-AE-B_T1 | 595-607 | http://purl.obolibrary.org/obo/UBERON_0000062 | denotes | organization |
GlyCosmos15-Sentences
| Id | Subject | Object | Predicate | Lexical cue |
|---|---|---|---|---|
| T1 | 0-82 | Sentence | denotes | A novel strategy to generate biologically active neo-glycosaminoglycan conjugates. |
| T2 | 83-199 | Sentence | denotes | Heparin and heparan sulfate are structurally related polysaccharides with a variety of biological effects/functions. |
| T3 | 200-337 | Sentence | denotes | Most of these effects are due to interactions, of varying specificity, between the negatively charged polysaccharide chains and proteins. |
| T4 | 338-562 | Sentence | denotes | While such interactions generally involve a single saccharide domain of decasaccharide size or less, ternary complexes of two protein molecules binding to separate domains on a single polysaccharide chain are known to occur. |
| T5 | 563-763 | Sentence | denotes | To facilitate studies on domain organization and its importance for biological function a strategy was developed to chemically conjugate defined heparin oligomers in linear and chemoselective fashion. |
| T6 | 764-1030 | Sentence | denotes | The procedure requires that the oligosaccharide to provide the reducing-terminal domain of the conjugate is generated by lyase degradation of a parent polysaccharide, whereas the nonreducing-terminal domain is obtained through deaminative cleavage with nitrous acid. |
| T7 | 1031-1273 | Sentence | denotes | The applicability of the method was demonstrated by constructing a conjugate composed of two heparin 12-mers, of which the reducing-terminal component contained the antithrombin-binding region, whereas the nonreducing-terminal domain did not. |
| T8 | 1274-1411 | Sentence | denotes | Contrary to any of the unconjugated oligomers, the product was found to efficiently promote the inactivation of thrombin by antithrombin. |
GlyCosmos15-GlycoEpitope
| Id | Subject | Object | Predicate | Lexical cue | glycoepitope_id |
|---|---|---|---|---|---|
| T1 | 95-110 | http://purl.jp/bio/12/glyco/glycan#Glycan_epitope | denotes | heparan sulfate | http://www.glycoepitope.jp/epitopes/EP0086 |